Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 60, Issue 5, Pages 3174-3177Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.03029-15
Keywords
-
Categories
Funding
- Achaogen
- Actavis
- Actelion
- Allergan
- American Proficiency Institute (API)
- AmpliPhi
- Anacor
- Astellas
- AstraZeneca
- Basilea
- Bayer
- BD
- Cardeas
- Cellceutix
- CEM-102 Pharmaceuticals
- Cempra
- Cerexa
- Cidara
- Cormedix
- Cubist
- Debiopharm
- Dipexium
- Dong Wha
- Durata
- Enteris
- Exela
- Forest Research Institute
- Furiex
- Genentech
- GSK
- Helperby
- ICPD
- Janssen
- Lannett
- Longitude
- Medpace
- Meiji Seika Kasha
- Melinta
- Merck
- Motif
- Nabriva
- Novartis
- Paratek
- Pfizer
- Pocared
- PTC Therapeutics
- Rempex
- Roche
- Salvat
- Scynexis
- Seachaid
- Shionogi
- Tetraphase
- Medicines Co.
- Theravance
- ThermoFisher
- VenatoRX
- Vertex
- Wockhardt
- Zavante
Ask authors/readers for more resources
Measurement of vancomycin susceptibility has been shown to be highly predictive as a surrogate measure of oritavancin susceptibility among clinically indicated Gram-positive species. Results of studying over 30,000 pathogens (from 2011 to 2014) by cross-susceptibility analysis and determining the poor reproducibility of oritavancin-nonsusceptible results showed nearly perfect surrogate testing accuracy (99.86 to 99.94%). Any isolate of an indicated organism species with locally reproducible oritavancin- nonsusceptible results (extremely rare) should be referred to a reference laboratory for confirmation of the results and determination of the resistance mechanism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available